The estimated Net Worth of Emily Minkow is at least $292 mil dollars as of 24 December 2019. Ms. Minkow owns over 13,000 units of Prevail Therapeutics Inc stock worth over $291,980 and over the last 5 years she sold PRVL stock worth over $0. In addition, she makes $0 as Chief Business Officer at Prevail Therapeutics Inc.
Emily has made over 1 trades of the Prevail Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 13,000 units of PRVL stock worth $2,340 on 24 December 2019.
The largest trade she's ever made was exercising 13,000 units of Prevail Therapeutics Inc stock on 24 December 2019 worth over $2,340. On average, Emily trades about 4,333 units every 0 days since 2019. As of 24 December 2019 she still owns at least 13,000 units of Prevail Therapeutics Inc stock.
You can see the complete history of Ms. Minkow stock trades at the bottom of the page.
Emily Minkow serves as Chief Business Officer of the Company. Ms. Minkow previously served as our Executive Vice President of Business Development and Strategy since November 2017. Prior to joining us, Ms. Minkow worked at Celgene Corporation, a global biopharmaceutical company, from August 2010 to October 2017, where she most recently served as Executive Director of Business Development. At Celgene, Ms. Minkow also served as Principal to the Chairman and CEO and as Director of Global Marketing. Prior to Celgene, she was a consultant for Frankel Group, where she advised biotech and pharmaceutical companies on clinical and commercial strategy. Ms. Minkow received an M.B.A. from Harvard Business School and a B.A. in public and international policy from Princeton University.
Emily Minkow is 37, she's been the Chief Business Officer of Prevail Therapeutics Inc since 2018. There are 12 older and no younger executives at Prevail Therapeutics Inc. The oldest executive at Prevail Therapeutics Inc is Franz Hefti, 72, who is the Chief Development Officer.
Emily's mailing address filed with the SEC is C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK, NY, 10016.
Over the last 5 years, insiders at Prevail Therapeutics Inc have traded over $0 worth of Prevail Therapeutics Inc stock and bought 36,931,845 units worth $816,407,705 . The most active insiders traders include Acquisition Corp Eli Lilly ..., Peter A. Thompson y Advisors Llc Orbi Med Capit.... On average, Prevail Therapeutics Inc executives and independent directors trade stock every 96 days with the average trade being worth of $138,767,762. The most recent stock trade was executed by Acquisition Corp Eli Lilly ... on 22 January 2021, trading 34,284,789 units of PRVL stock currently worth $771,407,753.
Prevail Therapeutics Inc executives and other stock owners filed with the SEC include: